Paper33529675
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
Rockey DC and 1 other. Gastroenterology, 2021. Cited by 124 papers, by iCite.
Cite this record
ConductScience Library. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Papers, record 33529675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33529675
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepacivirus | Major topic |
| Hepatitis C | Major topic |
| Liver | Major topic |
| Liver Cirrhosis | Major topic |
| Translational Research, Biomedical | Major topic |
| Animals | |
| Host-Pathogen Interactions | |
| Humans | |
| Liver Regeneration | |
| Remission Induction | |
| Treatment Outcome |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 DK056621 | NIDDK NIH HHS | United States | R01DK056621 | PubMed and NIH | NIH RePORTER |
| P30 DK123704 | NIDDK NIH HHS | United States | P30DK123704 | PubMed and NIH | NIH RePORTER |
| R01 DK098819 | NIDDK NIH HHS | United States | R01DK098819 | PubMed and NIH | NIH RePORTER |
| P20 GM130457 | NIGMS NIH HHS | United States | P20GM130457 | PubMed and NIH | NIH RePORTER |
| R01 DK128289 | NIDDK NIH HHS | United States | R01DK128289 | PubMed and NIH | NIH RePORTER |
| R56 DK056621 | NIDDK NIH HHS | United States | R01DK056621 | PubMed and NIH | NIH RePORTER |
| R01 DK113159 | NIDDK NIH HHS | United States | R01DK113159 | PubMed and NIH | NIH RePORTER |
| R01 DK057830 | NIDDK NIH HHS | United States | R01DK057830 | PubMed and NIH | NIH RePORTER |
| R56DK056621 | NIH | NIH RePORTER |
References174
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20818376 | Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. | Nat Med | 2010 | https://conductscience.org/library/papers/20818376 | PubMed |
| 2 | 28960366 | Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. | Hepatology | 2018 | https://conductscience.org/library/papers/28960366 | PubMed |
| 3 | 30878469 | AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30878469 | PubMed |
| 4 | 24265236 | Hepatic stellate cells and liver fibrosis. | Compr Physiol | 2013 | https://conductscience.org/library/papers/24265236 | PubMed |
| 5 | 23712051 | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. | J Hepatol | 2013 | https://conductscience.org/library/papers/23712051 | PubMed |
| 6 | 28195349 | Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. | Hepatology | 2017 | https://conductscience.org/library/papers/28195349 | PubMed |
| 7 | 28585556 | Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. | Am J Gastroenterol | 2017 | https://conductscience.org/library/papers/28585556 | PubMed |
| 8 | 18376398 | Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. | Nat Biotechnol | 2008 | https://conductscience.org/library/papers/18376398 | PubMed |
| 9 | 28734831 | Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. | Gastroenterology | 2017 | https://conductscience.org/library/papers/28734831 | PubMed |
| 10 | 11738102 | Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. | J Hepatol | 2001 | https://conductscience.org/library/papers/11738102 | PubMed |
| 11 | 28390144 | Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. | Hepatology | 2017 | https://conductscience.org/library/papers/28390144 | PubMed |
| 12 | 27500382 | Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. | J Viral Hepat | 2016 | https://conductscience.org/library/papers/27500382 | PubMed |
| 13 | 28803953 | Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. | J Hepatol | 2017 | https://conductscience.org/library/papers/28803953 | PubMed |
| 14 | 25500203 | KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. | Gut | 2015 | https://conductscience.org/library/papers/25500203 | PubMed |
| 15 | 31654313 | Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy. | Dig Dis Sci | 2020 | https://conductscience.org/library/papers/31654313 | PubMed |
| 16 | 31122893 | Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. | Lancet Respir Med | 2019 | https://conductscience.org/library/papers/31122893 | PubMed |
| 17 | 31849997 | Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31849997 | PubMed |
| 18 | 30024770 | Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts. | Am J Physiol Gastrointest Liver Physiol | 2018 | https://conductscience.org/library/papers/30024770 | PubMed |
| 19 | 27347680 | Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. | PLoS One | 2016 | https://conductscience.org/library/papers/27347680 | PubMed |
| 20 | 12198653 | Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. | Hepatology | 2002 | https://conductscience.org/library/papers/12198653 | PubMed |
Cited by91
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942373 | Lower Plasma Brain-Derived Neurotrophic Factor Levels During Critical Illness Are Associated with Subsequent Dialysis Requirement. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42942373 | PubMed |
| 42883939 | Cell Sheet Technology as a Platform for Functional Regeneration. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883939 | PubMed |
| 42725204 | Recurrent and De Novo Cirrhosis After Liver Transplantation. | Portal Hypertens Cirrhosis | 2026 | https://conductscience.org/library/papers/42725204 | PubMed |
| 42558794 | Ferroptosis in liver diseases: molecular mechanisms, biomarker potential, and clinical translation. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42558794 | PubMed |
| 42417164 | Fibroblasts: a diverse population of cells balancing homeostasis, wound healing, regeneration, inflammation, fibrosis, and cancer across organs. | JCI Insight | 2026 | https://conductscience.org/library/papers/42417164 | PubMed |
| 42417159 | Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution. | JCI Insight | 2026 | https://conductscience.org/library/papers/42417159 | PubMed |
| 42218281 | Predictors and outcomes of hepatic decompensation following transarterial locoregional therapy in hepatocellular carcinoma. | Sci Rep | 2026 | https://conductscience.org/library/papers/42218281 | PubMed |
| 42135704 | Liver stiffness by non-invasive tests predicts hepatocellular carcinoma and liver-related complications following viral eradication with direct-acting antivirals in chronic hepatitis C: a retrospective cohort study. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42135704 | PubMed |
| 41929481 | Hepatitis C virus core protein-induced myeloid-derived suppressor cells promote hepatic fibrosis by regulating hepatic stellate cell function via TGF-β. | Front Immunol | 2026 | https://conductscience.org/library/papers/41929481 | PubMed |
| 41629815 | Risk factors for significant hepatic fibrosis in alcoholic liver disease and construction of a nomogram prediction model. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/41629815 | PubMed |
| 41601646 | Lipid and immune dysregulation and risk of metabolic disorders after HCV clearance in HIV/HCV-coinfected participants with cACLD: a retrospective study. | Front Immunol | 2025 | https://conductscience.org/library/papers/41601646 | PubMed |
| 41594255 | Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/41594255 | PubMed |
| 41459093 | Metabolic dysfunction and alcohol-associated liver disease (MetALD). | eGastroenterology | 2025 | https://conductscience.org/library/papers/41459093 | PubMed |
| 41368107 | Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41368107 | PubMed |
| 41327905 | Re-evaluating DAA therapy in active hepatocellular carcinoma: from controversy to clinical considerations. | J Liver Cancer | 2026 | https://conductscience.org/library/papers/41327905 | PubMed |
| 41303147 | Evolution of Liver Fibrosis in Romanian HCV Patients Following Treatment with Direct-Acting Antivirals. | J Clin Med | 2025 | https://conductscience.org/library/papers/41303147 | PubMed |
| 41301814 | Effect of Hepatitis C Virus Genotype, Cirrhosis, and Viral Cure on Serum Phosphatidylinositol Species Profiles. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301814 | PubMed |
| 41236657 | Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis. | Eur Radiol | 2026 | https://conductscience.org/library/papers/41236657 | PubMed |
| 41126716 | 2025 KASL clinical practice guidelines for management of hepatitis C. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/41126716 | PubMed |
| 41096743 | Shared and Context-Specific Mechanisms of EMT and Cellular Plasticity in Cancer and Fibrotic Diseases. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41096743 | PubMed |
Genes24
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33529675
GET https://conductscience.org/api/papers/v1/33529675/references?page=2